N/A
N=603
Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets
Alzheimer Disease
Bottom Line
View on ClinicalTrials.gov: NCT01089582 ↗Enrolled (actual)
603
Serious AEs
0.3%
Results posted
Aug 2010
Primary outcome: Primary: Number of Participants for Change From Baseline for Clinical Global Impressions of Improvement (CGI-I) at Week 12 — 26; 5; 27; 103 participants — p=0.0023
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- No intervention (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Jul 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants for Change From Baseline for Clinical Global Impressions of Improvement (CGI-I) at Week 12 |
26; 5; 27; 103; 277; 142 | 0.0023 sig |
| PRIMARY Number of Participants for Change From Baseline for the Caregiver's Assessment of Improvement at Week 12 |
39; 54; 343; 140; 27; 0 | 0.0382 sig |
| PRIMARY Change From Baseline in the Participant's Assessment for Quality of Life for Alzheimer's Dementia (QoL-AD) Overall and Subscale Scores at Week 12 |
0.1; 0.2; 0.3; 0.2; 0.3; 0.1 | 0.1805 |
| PRIMARY Change From Baseline in the Caregiver's Assessment for Quality of Life for Alzheimer's Dementia (QoL-AD) Overall and Subscale Scores at Week 12 |
0.1; 0.2; 0.3; 0.2; 0.3; 0.1 | 0.0137 sig |
| SECONDARY Change in ARICEPT Dosing: Number of Participants for Time to First ARICEPT Dose Escalation |
198; 77; 267; 19; 13; 29 | — |
| SECONDARY Change in ARICEPT Dosing: Number of Participants at Each Final Dose of ARICEPT |
8; 193; 400; 2 | — |
| SECONDARY Number of Participants for the Physician's Assessment of Tolerance to ARICEPT at Week 12 |
9; 386; 161; 26; 13; 8 | — |
Summary
This study assessed the Hr QoL (Health related Quality of life) of subjects with mild to moderate AD, who received ARICEPT under usual clinical practice.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of Alzheimer's Disease
Exclusion Criteria
- There are no exclusion criteria
Data sourced from ClinicalTrials.gov (NCT01089582). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.